

AVAXIM® Junior


Please refer to the Summary of Product Characteristics before prescribing

Hepatitis A vaccine
(inactivated, adsorbed)

AVAXIM® Junior
prescribing information



AVAXIM® Junior
for children aged
1–15 years¹



Visit VaxiShop to place an order



Discover AVAXIM® Junior

AVAXIM® Junior is indicated for active immunisation against infection caused by hepatitis A virus in **children aged 1–15 years**¹

To provide long-term protection, a second dose (booster) of vaccine is recommended. The booster should be given between **6 months to 10 years** after the first dose¹

AVAXIM® Junior can also be **used as a booster** in children who have previously been immunised with another inactivated hepatitis A vaccine¹



Dose 1



Initial protection starts within **2 weeks** after administration¹



Dose 2



Booster dose administration extendable **up to 10 years** after initial immunisation¹

About hepatitis A

In 2019, Global burden of disease (GBD) data estimated **159 million acute HAV infections, resulting in 39 000 deaths**²

The WHO recommends that travellers to areas of **intermediate/high hepatitis A endemicity** should be vaccinated against the disease²

Children play a major role in the transmission of hepatitis A because their individual hygiene skills are usually not strong and because infection in this group is usually asymptomatic³



Find travel support items from Sanofi at www.medisa.com




Rapid and sustained protection for your paediatric patients^{4–11}

AVAXIM® Junior has demonstrated tolerability and efficacy in children aged 1–15 years^{4–11}

Based on data from a pooled analysis, most undesirable effects following administration of AVAXIM® Junior were limited to the first few days following immunisation, with spontaneous recovery. Reactions were more rarely reported after the booster dose than after the first dose.¹¹

For a full list of side effects please refer to the SMPC¹

Seroconversion rates across different ages after primary immunisation with AVAXIM® Junior^{*†4}



Footnotes

^{*}Seroconversion defined as anti-HAV antibody titres <20 mIU/ml (seronegative) increasing to titres ≥20 mIU/ml.
[†]Data from initially HAV-seronegative 189 Israeli children, aged 18 months to 15 years in a monocentric, open trial. Rates of systemic reactions were 23.8% after the first dose and 11.4% after the booster dose. Pain at the injection site was the most common local reaction, though this did not persist longer than 3 days. Gastrointestinal tract disorder, headache, and fever were the most common systemic reactions. Pain at the injection site was the most common local reaction, but never persisted more than 3 days.
[‡]Pooled analysis integrated data from 5,458 children aged 1–15 years who received at least one injection of AVAXIM® Junior during clinical trials.

Abbreviations

HAV, hepatitis A virus, WHO, World Health Organization.

References

1. AVAXIM® Junior Summary of Product Characteristics. 2. World Health Organization. Wkly Epidemiol Rec 2012;87(28/29):261–76. 3. Michaëls K, et al. *Sci Rep* 2018;8(1):16496. 4. Dagan R, et al. *Vaccine* 1999;17(15–16):1919–25. 5. López EL, et al. *Pediatr Infect Dis J* 2001;20(1):48–52. 6. Lokekha S, et al. *J Trop Pediatr* 2003;49(6):333–9. 7. Espul C, et al. *Hum Vaccin Immunother* 2017;13(11):2707–12. 8. Soysal A, et al. *Eur J Pediatr* 2007;166(6):533–9. 9. Dagan R, et al. *Vaccine* 2005;23(44):5144–8. 10. López EL, et al. *Pediatr Infect Dis J* 2010;29(6):568–70. 11. López EL, et al. *Pediatr Infect Dis J* 2015;34(4):417–25. 12. AVAXIM® Summary of Product Characteristics.

AVAXIM® Junior Key Attributes




Seroprotection
Initial protection starts within **2 weeks** after administration^{1–3}



Interchangeable with other paediatric inactivated hepatitis A vaccines as a booster dose with **flexible booster timing**^{1,6–8}



Long-lasting protection, assessed up to **15 years** after initial immunisation^{9–11}



Shown to be **well tolerated** in young children¹

For a full list of side effects please refer to the SMPC¹

Safety information

A few of the very common adverse events: very common (≥ 1/10)

- Abnormal crying
- Headache
- Injection site pain
- Malaise

For a full list of side effects please refer to the SMPC¹



Visit VaxiShop to place an order



For over 100 years, Sanofi has been dedicated to the reach of life-savings vaccines. We offer a wide range of travel vaccines to meet your immunisation needs, including AVAXIM® (hepatitis A vaccine [inactivated, adsorbed] Avaxim® Prescribing Information) which offers hepatitis A protection for adults¹². We are pleased to let you know that Sanofi provides a hepatitis A vaccine for children too.

Footnotes

^{*}Seroconversion defined as anti-HAV antibody titres <20 mIU/ml (seronegative) increasing to titres ≥20 mIU/ml.
[†]Data from initially HAV-seronegative 189 Israeli children, aged 18 months to 15 years in a monocentric, open trial. Rates of systemic reactions were 23.8% after the first dose and 11.4% after the booster dose. Pain at the injection site was the most common local reaction, though this did not persist longer than 3 days. Gastrointestinal tract disorder, headache, and fever were the most common systemic reactions. Pain at the injection site was the most common local reaction, but never persisted more than 3 days.
[‡]Pooled analysis integrated data from 5,458 children aged 1–15 years who received at least one injection of AVAXIM® Junior during clinical trials.

Abbreviations

HAV, hepatitis A virus, WHO, World Health Organization.

Reporting side effects

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on **0800 0902 314**. Alternatively send via email to: UK-drugsafety@sanofi.com